Tags: BGX | BIZNEWS | BNALL | BNCOPY | BNCOPY2 | BNSTAFF | BNTEAMS

Combination Strategy to Attack Multiple Sclerosis

Combination Strategy to Attack Multiple Sclerosis

(Copyright Fotolia)

Sunday, 23 October 2016 01:53 PM

Actelion Ltd. is seeking more effective treatments for people suffering from multiple sclerosis by following a strategy that’s worked in treating HIV, cancer and heart failure -- combining medicines to increase their potency.

The company has begun late-stage testing for its experimental medicine, ponesimod, which may work for people suffering from the most common type of multiple sclerosis, which affects roughly 85 percent of those diagnosed with the hard-to-detect and incurable disease. Ponesimod is being studied with Biogen Inc.’s Tecfidera as the first two-pill combination for MS, Actelion said Thursday in a statement.

“We have the ideal drug, ponesimod, which can be used in combination," Chief Executive Officer Jean-Paul Clozel said in an interview on Bloomberg Television on Thursday. "It’s a very busy market” but with one patient out of five having a new relapse every year, there is a need for more effective therapies, he said.

Actelion is diversifying its business, which leans heavily on pulmonary arterial hypertension treatments including Tracleer and newer replacements Uptravi and Opsumit. The Allschwil, Switzerland-based company is striving for a share of the multiple sclerosis market, which is dominated by bigger players such as Novartis AG and Biogen. Other potential new entrants such as Roche Holding AG are likely to shake up the market. Ponesimod is also being studied in comparison with another pill, Sanofi’s Aubagio.

Actelion reported third-quarter sales of 606 million Swiss francs ($612 million) and raised its forecast for the full year thanks to sales of its newest drug for pulmonary arterial hypertension, Uptravi.

Actelion fell 0.2 percent to 163.50 at 10:02 a.m. in Zurich. The stock has gained 17 percent this year.

 

© Copyright 2019 Bloomberg News. All rights reserved.

   
1Like our page
2Share
Health-News
Actelion Ltd. is seeking more effective treatments for people suffering from multiple sclerosis by following a strategy that's worked in treating HIV, cancer and heart failure -- combining medicines to increase their potency.The company has begun late-stage testing for its...
BGX, BIZNEWS, BNALL, BNCOPY, BNCOPY2, BNSTAFF, BNTEAMS, BUSINESS, COS, EHEALTH, EUBNX, EUROPEME, EUROSTORY, EXCLUSIVE, FINNEWS, GOWEB, SRCRANK1, HEATOP, HEATOPZ2, HEATOPZ3, HEATOPZ4, HEATOPZ5, HEATOPZ6, HLNOVEL, HLNOVELTY9, LST, NOVEL, NOVELTY7, ONWEB, ORIGINAL, READ, READ100, READ150, READ25, READ50, SWTOP, SWTOPZ2, SWTOPZ3, TOP, TOPBIZMKT, WWTOP, WWTOPBIZ, WWTOPZ3, AGRKEY, WHICH2, BBGTVCITE, BBPROFILE, BGOVBILLGO, BGOVCODES, BNHESAID, BONDWIRES, WEBELIG, CMDGLOMAC, CMDKEY, TIMENI, EQUITYKEY, GENHEA, GLOMACBB, TIMECO, ILLNESS, INDUSTRIES, INTERNAL, MAJOR, METALKEY, MISC, MULTSCL, NERVILL, NRGKEY, OILKEY, HEA, APSY, DRG, CARDIO, HYPERTEN
272
2016-53-23
Sunday, 23 October 2016 01:53 PM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved